7 Results for "

lipoma

" in MedChemExpress (MCE) Product Catalog:
Products (7)

7 Results for "lipoma" in MCE Product Catalog:

130
Alpelisib
Alpelisib
0 Images
130 Cited Publications
Cat. No.: HY-15244
CAS No.: 1217486-61-7
Purity:  99.88%
Synonyms: BYL-719
Target:  

PI3K Apoptosis

Research Areas:  

Infection Neurological Disease Metabolic Disease Cancer

Alpelisib (BYL-719) is an orally active PI3Kα-selective inhibitor that blocks the conversion of PIP2 to PIP3, thereby inhibiting pathways including PI3K/AKT/mTOR, MAPK/ERK, Notch and JAK-STAT. Alpelisib also induces apoptosis, G0/G1 phase arrest and senescence; it significantly inhibits the proliferation, self-renewal, stemness and epithelial-mesenchymal transition (EMT) of tumor cells, reduces cancer stem cell populations and decreases the expression of stem cell markers. Alpelisib not only enhances the sensitivity to Eribulin (HY-13442) and exerts a synergistic effect with Paclitaxel (HY-B0015), but may also induce drug resistance by upregulating the SGK3/GSK3β/β-catenin signaling pathway. Alpelisib can be applied to research related to breast cancer, gastric cancer and lipomas associated with PTEN hamartoma tumor syndrome .
130
Alpelisib hydrochloride
Alpelisib hydrochloride
0 Images
130 Cited Publications
Cat. No.: HY-15244A
CAS No.: 1584128-91-5
Synonyms: BYL-719 hydrochloride
Target:  

PI3K Apoptosis

Research Areas:  

Infection Neurological Disease Metabolic Disease Cancer

Alpelisib (BYL-719) hydrochloride is an orally active PI3Kα-selective inhibitor that blocks the conversion of PIP2 to PIP3, thereby inhibiting pathways including PI3K/AKT/mTOR, MAPK/ERK, Notch and JAK-STAT. Alpelisib hydrochloride also induces apoptosis, G0/G1 phase arrest and senescence; it significantly inhibits the proliferation, self-renewal, stemness and epithelial-mesenchymal transition (EMT) of tumor cells, reduces cancer stem cell populations and decreases the expression of stem cell markers. Alpelisib hydrochloride not only enhances the sensitivity to Eribulin (HY-13442) and exerts a synergistic effect with Paclitaxel (HY-B0015), but may also induce drug resistance by upregulating the SGK3/GSK3β/β-catenin signaling pathway. Alpelisib hydrochloride can be applied to research related to breast cancer, gastric cancer and lipomas associated with PTEN hamartoma tumor syndrome .
Alpelisib (Standard)
Alpelisib (Standard)
0 Images
Cat. No.: HY-15244R
CAS No.: 1217486-61-7
Synonyms: BYL-719 (Standard)
Target:  

Reference Standards PI3K Apoptosis

Alpelisib (BYL-719) (Standard) is the analytical standard of Alpelisib (HY-15244). This product is intended for research and analytical applications. Alpelisib (BYL-719) is an orally active PI3Kα-selective inhibitor that blocks the conversion of PIP2 to PIP3, thereby inhibiting pathways including PI3K/AKT/mTOR, MAPK/ERK, Notch and JAK-STAT. Alpelisib also induces apoptosis, G0/G1 phase arrest and senescence; it significantly inhibits the proliferation, self-renewal, stemness and epithelial-mesenchymal transition (EMT) of tumor cells, reduces cancer stem cell populations and decreases the expression of stem cell markers. Alpelisib not only enhances the sensitivity to Eribulin (HY-13442) and exerts a synergistic effect with Paclitaxel (HY-B0015), but may also induce drug resistance by upregulating the SGK3/GSK3β/β-catenin signaling pathway. Alpelisib can be applied to research related to breast cancer, gastric cancer and lipomas associated with PTEN hamartoma tumor syndrome .
LPP Antibody (YA993)
LPP Antibody (YA993)
0 Images
Cat. No.: HY-P81285
Synonyms: LPP; lipoma-preferred partner; LIM domain-containing preferred translocation partner in lipoma

Host:  

Mouse

Application:  

WB, IHC-F, IHC-P, ICC/IF, IP

Reactivity:  

Human, Mouse, Rat, Monkey, Hamster

LPP Antibody (YA994)
LPP Antibody (YA994)
0 Images
Cat. No.: HY-P81285A
Synonyms: LPP; lipoma-preferred partner; LIM domain-containing preferred translocation partner in lipoma

Host:  

Rabbit

Application:  

WB, IHC-P, ICC/IF

Reactivity:  

Human, Mouse, Rat

LPP Antibody (YA4955)
LPP Antibody (YA4955)
0 Images
Cat. No.: HY-P85263
Synonyms: LPP; lipoma-preferred partner; LIM domain-containing preferred translocation partner in lipoma

Host:  

Rabbit

Application:  

WB, IHC-P, IHC-F, IF-Tissue

Reactivity:  

Human, Mouse, Rat

Alpelisib (GMP)
Alpelisib (GMP)
0 Images
Cat. No.: HY-15244G
CAS No.: 1217486-61-7
Alpelisib GMP is Alpelisib (HY-15244) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Alpelisib (BYL-719) is an orally active PI3Kα-selective inhibitor that blocks the conversion of PIP2 to PIP3, thereby inhibiting pathways including PI3K/AKT/mTOR, MAPK/ERK, Notch and JAK-STAT. Alpelisib also induces apoptosis, G0/G1 phase arrest and senescence; it significantly inhibits the proliferation, self-renewal, stemness and epithelial-mesenchymal transition (EMT) of tumor cells, reduces cancer stem cell populations and decreases the expression of stem cell markers. Alpelisib not only enhances the sensitivity to Eribulin (HY-13442) and exerts a synergistic effect with Paclitaxel (HY-B0015), but may also induce drug resistance by upregulating the SGK3/GSK3β/β-catenin signaling pathway. Alpelisib can be applied to research related to breast cancer, gastric cancer and lipomas associated with PTEN hamartoma tumor syndrome .
Assay Types